ERBB2 and breast carcinoma: Garcia et al showed that dual mTORC1 and mTORC2 inhibition in combination with anti-HER2 therapy resulted in suppression of cancer cell growth in HER2-positive breast cancer; however, the efficacy of TAK228 in TNBC with and without PTEN-loss, in combination therapy has not been evaluated [9].